2 patents currently held
91 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2029. from the record
Of the 91 now held by other companies, 80 name Avent Inc. as their current owner, and 11 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Jun 2029
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2029 · High confidence
Also notable
Ends no later than Sep 2030 · Medium confidence
New Benzimidazole Derivatives
US 7,906,654
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2029.
Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof
US 8,633,235
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Apr 2037 · High confidence
The most cited patent in this portfolio, cited by 86 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037.
now held by Avent, Inc.
Also notable
Ends Nov 2035 · High confidence
Cited by 50 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2035.
now held by Avent, Inc.
Also notable
Ends Jul 2036 · High confidence
Cited by 46 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2036.
now held by Avent, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof | 1 in force | to Sep 2030 |
| New Benzimidazole Derivatives | 1 in force | to Jun 2029 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,906,654 | New Benzimidazole Derivatives held by Neomed Institute In force · High confidence | In force | High confidence | |
| US 8,633,235 | Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof held by Neomed Institute In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 91 patents in force now held by others · 5 patents ended · 6 applications pending · 20 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
4 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed